×

Optimal drug treatment regimens for HIV depend on adherence. (English) Zbl 1451.92170

Summary: Drug therapies aimed at suppressing the human immunodeficiency virus (HIV) are highly effective, often reducing the viral load to below the limits of detection for years. Adherence to such antiviral regimens, however, is typically far from ideal. We have previously developed a model that predicts optimal treatment regimens by weighing drug toxicity against \(\mathit{CD}4^+\) T-cell counts, including the probability that drug resistance will emerge. We use this model to investigate the influence of adherence on therapy benefit. For a drug with a given half-life, we compare the effects of varying the dose amount and dose interval for different rates of adherence, and compute the optimal dose regimen for adherence between 65% and 95%. Our results suggest that for optimal treatment benefit, drug regimens should be adjusted for poor adherence, usually by increasing the dose amount and leaving the dose interval fixed. We also find that the benefit of therapy can be surprisingly robust to poor adherence, as long as the dose interval and dose amount are chosen accordingly.

MSC:

92C50 Medical applications (general)
PDFBibTeX XMLCite
Full Text: DOI

References:

[1] Ammassari, A.; Murri, R.; Pezzotti, P.; Trotta, M. P.; Ravasio, L.; De Longis, P.; Lo Caputo, S.; Narciso, P.; Pauluzzi, S.; Carosi, G.; Nappa, S.; Piano, P.; Izzo, C. M.; Lichtner, M.; Rezza, G.; Monforte, A., Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection, J. Acquir. Immune Defic. Syndr., 5, 28, 445-449 (2001)
[2] Arnsten, J. H.; Demas, P. A.; Farzadegan, H.; Grant, R. W.; Gourevitch, M. N.; Chang, C. J.; Buono, D.; Eckholdt, H.; Howard, A. A.; Schoenbaum, E. E., Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring, Clin. Infect. Dis., 338, 8, 1417-1423 (2001)
[3] Bangsberg, D. R.; Hecht, F. M.; Charlebois, E. D.; Zolopa, A. R.; Holodniy, M.; Sheiner, L.; Bamberger, J. D.; Chesney, M. A.; Moss, A., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population, AIDS, 14, 4, 357-366 (2000)
[4] Bangsberg, D. R.; Charlebois, E. D.; Grant, R. M.; Holodniy, M.; Deeks, S. G.; Perry, S.; Conroy, K. N.; Clark, R.; Guzman, D.; Zolopa, A.; Moss, A., High levels of adherence do not prevent accumulation of HIV drug resistance mutations, AIDS, 17, 13, 1925-1932 (2003)
[5] Bangsberg, D. R.; Moss, A. R.; Deeks, S. G., Paradoxes of adherence and drug resistance to HIV antiretroviral therapy, J. Antimicrob. Chemother., 53, 5, 696-699 (2004)
[6] de Olalla, G. P.; Knobel, H.; Carmona, A.; Guelar, A.; Lopez-Colomes, J. L.; Cayla, J. A., Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients, J. Acquir. Immune Defic. Syndr., 30, 1, 105-110 (2002)
[7] DeGruttola, V.; Dix, L.; D’Aquila, R.; Holder, D.; Phillips, A.; Ait-Khaled, M.; Baxter, J.; Clevenbergh, P.; Hammer, S.; Harrigan, R.; Katzenstein, D.; Lanier, R.; Miller, M.; Para, M.; Yerly, S.; Zolopa, A.; Murray, J.; Patick; Aand Miller, V.; Castillo, S.; Pedneault, L.; Mellors, J., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, Antivir. Ther., 5, 1, 41-48 (2000)
[8] Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J.P., Pialoux, G., Raffi, F., Brun-Ve’zinet, Franc, O., and for the Trile‘ge (Agence Nationale de Recherches sur le SIDA 072) Study Team, 2000. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. J. Am. Med. Assoc. 283, 205-211.
[9] Eldred, L.; Cheever, L., Update on adherence to HIV therapy, Hopkins HIV Rep., 10, 1, 10-11 (1998)
[10] Ferguson, N. M.; Donnelly, C. A.; Hooper, J.; Ghani, A. C.; Fraser, C.; Bartley, L. M.; Rode, R. A.; Vernazza, P.; Lapins, D.; Mayer, S. L.; Anderson, R. M., Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients, J. R. Soc. Interface, 2, 4, 349-363 (2005)
[11] Giordano, T. P.; Guzman, D.; Clark, R.; Charlebois, E. D.; Bangsberg, D. R., Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale, HIV Clinical Trials, 5, 2, 74-79 (2004)
[12] Grabar, S.; Pradier, C.; Le Corfec, E.; Lancar, R.; Allavena, C.; Bentata, M.; Berlureau, P.; Dupont, C.; Fabbro-Peray, P.; Poizot-Martin, I.; Costagliola, D., Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor, AIDS, 14, 2, 141-149 (2000)
[13] Gross, R.; Bilker, W. B.; Friedman, H. M.; Strom, B. L., Effect of adherence to newly initiated antiretroviral therapy on plasma viral load, AIDS, 15, 16, 2109-2117 (2001)
[14] Harrigan, P. R.; Hogg, R. S.; Dong, W. W.; Yip, B.; Wynhoven, B.; Woodward, J.; Brumme, C. J.; Brumme, Z. L.; Mo, T.; Alexander, C. S.; Montaner, J. S., Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy, J. Infect. Dis., 191, 3, 339-347 (2005)
[15] Heffernan, J. M.; Wahl, L. M., Natural variation in HIV infection: Monte Carlo estimates that include CD8 effector cells, J. Theor. Biol., 243, 191-204 (2006) · Zbl 1447.92428
[16] Hinkin, C. H.; Hardy, D. J.; Mason, K. I.; Castellon, S. A.; Durvasula, R. S.; Lam, M. N.; Stefaniak, M., Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse, AIDS, 18, Suppl. 1, S19-S25 (2004)
[17] Howard, A. A.; Arnsten, J. H.; Lo, Y.; Vlahov, D.; Rich, J. D.; Schuman, P.; Stone, V. E.; Smith, D. K.f.; Schoenbaum, E. E.f.t. H.S. G., A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women, AIDS, 16, 16, 2175-2182 (2002)
[18] Huang, Y.; Rosenkranz, S. L.; Wu, H., Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity, Math. Biosci., 184, 2, 165-186 (2003) · Zbl 1030.92016
[19] Karlin, S.; Taylor, H. M., A First Course in Stochastic Processes (1975), Academic Press: Academic Press New York · Zbl 0315.60016
[20] Kathleen, J. R., Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens, AIDS Patient Care STDs, 14, 3, 155-168 (2000)
[21] Krakovska, O., Wahl, L.M., 2007. Costs versus benefits: best possible and best practical treatment regimens for HIV. J. Math. Biol., in press, doi:10.1007/s00285-006-0059-1. · Zbl 1115.92030
[22] Lohse, N.; Obel, N.; Kronborg, G.; Laursen, A.; Pedersen, C.; Larsen, C. S.; Kvinesdal, B.; Sorensen, H. T.; Gerstoft, J., Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals, AIDS, 19, 8, 815-822 (2005)
[23] Maitland, D.; Moyle, G.; Hand, J.; Mandalia, S.; Boffito, M.; M, N.; Gazzard, B., Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial, AIDS, 19, 11, 1183-1188 (2005)
[24] Martin-Carbonero, L.; Soriano, V.; Valencia, E.; Garcia-Samaniego, J.; Lopez, M.; Gonzalez-Lahoz, J., Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients, AIDS Res. Hum. Retroviruses, 17, 16, 1467-1471 (2001)
[25] Martinez-Picado, J.; Negredo, E.; Ruiz, L.; Shintani, A.; Fumaz, C. R.; Zala, C.; Domingo, P.; Vilaro, J.; Llibre, J. M.; Viciana, P.; Hertogs, K.; Boucher, C.; D’Aquila, R. T.; Clotet, B., Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial, Ann. Intern. Med., 139, 2, 81-89 (2003)
[26] Mocroft, A.; Ledergerber, B.; Viard, J. P.; Staszewski, S.; Murphy, M.; Chiesi, A.; Horban, A.; Hansen, A. B.; Phillips, A. N.; Lundgren, J. D., Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA Study Group, J. Infect. Dis., 190, 11, 1947-1956 (2004)
[27] Montaner, J.; Hill, A.; Acosta, E., Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios, Lancet, 357, 9266, 1438-1440 (2001)
[28] Montaner, J. S.; Reiss, P.; Cooper, D.; Vella, S.; Harris, M.; Conway, B.; Wainberg, M. A.; Smith, D.; Robinson, P.; Hall, D.; Myers, M.; Lange, J. M., A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial, J. Am. Med. Assoc., 279, 12, 930-937 (1998)
[29] Oyugi, J. H.; Byakika-Tusiime, J. B.; Charlebois, E. D.; Kityo, C.; Mugerwa, R.; Mugyenyi, P.; Bangsberg, D. R., Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting, JAIDS, 36, 5, 1100-1102 (2004)
[30] Paterson, D. L.; Swindells, S.; Mohr, J.; Brester, M.; Vergis, E. N.; Squier, C.; Wagener, M. M.; Singh, N., Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, Ann. Intern. Med., 133, 1, 21-30 (2000)
[31] Phillips, A.N., Staszewski, S., Weber, R., Kirk, O., Francioli, P., Miller, V., Vernazza, P., Lundgren, J.D., Ledergerber, B., Swiss HIV Cohort Study, Frankfurt HIV Clinic Cohort, and EuroSIDA Study Group, 2001a. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J. Am. Med. Assoc. 286(20), 2560-2567.
[32] Phillips, A. N.; Youle, M.; Johnson, M.; Loveday, C., Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development, AIDS, 15, 17, 2211-2220 (2001)
[33] Phillips, A.N., Dunn, D., Sabin, C., Pozniak, A., Matthias, R., Geretti, A.M., Clarke, J., Churchill, D., Williams, I., Hill, T., Green, H., Porter, K., Scullard, G., Johnson, M., Easterbrook, P., Gilson, R., Fisher, M., Loveday, C., Gazzard, B., Pillay, D., UK Collaborative Group on HIV Drug Resistance, and UK CHIC Study Group, 2005. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19(5), 487-494.
[34] Roca, B.; Gomez, C. J.; Arnedo, A., Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients, J. Infect., 41, 1, 50-54 (2000)
[35] Sethi, A.K., Celentano, D.D., Gange, S.J., Moore, R.D., Gallant, J.E., 2003. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (8), 1112-1118.
[36] Siegel, K.; Schrimshaw, E. W.; Raveis, V. H., Accounts for non-adherence to antiviral combination therapies among older HIV-infected adults, Psychol. Health Med., 5, 1, 29-42 (2000)
[37] Smith, R. J., Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?, Proc. R. Soc. London B Biol. Sci., 273, 1586, 617-624 (2006)
[38] Smith, R. J.; Wahl, L. M., Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects, Bull. Math. Biol., 66, 5, 1259-1283 (2004) · Zbl 1334.92239
[39] Smith, R. J.; Wahl, L. M., Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects, Bull. Math. Biol., 67, 4, 783-813 (2005) · Zbl 1334.92240
[40] Verotta, D.; Schaedeli, F., Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials, Math. Biosci., 176, 2, 163-183 (2002) · Zbl 1015.92022
[41] Wahl, L. M.; Nowak, M. A., Adherence and resistance: predictions for therapy outcome, Proc. Biol. Sci., 267, 1445, 835-843 (2000)
[42] Walsh, J. C.; Pozniak, A. L.; Nelson, M. R.; Mandalia, S.; Gazzard, B. G., Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance, J. Acquir. Immune Defic. Syndr., 30, 3, 278-287 (2002)
[43] Weiser, S.; Wolfe, W.; Bangsberg, D.; Thior, I.; Gilbert, P.; Makhema, J.; Kebaabetswe, P.; Dickenson, D.; Mompati, K.; Essex, M.; Marlink, R., Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana, JAIDS, 34, 3, 281-288 (2003)
[44] Wood, E.; Hogg, R. S.; Yip, B.; Harrigan, P. R.; O’Shaughnessy, M. V.; Montaner, J. S., Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the \(\mathit{CD} 4^+\) cell count is 0.200 to \(0.350 \times 10(9) \operatorname{cells} / \operatorname{L} \), Ann. Intern. Med., 139, 10, 810-816 (2003)
[45] Wu, H.; Huang, Y.; Acosta, E. P.; Rosenkranz, S. L.; Kuritzkes, D. R.; Eron, J. J.; Perelson, A. S.; Gerber, J. G., Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance, J. Acquir. Immune Defic. Syndr., 39, 3, 272-283 (2005)
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.